Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp ecently, the incidence of coronary artery disease (CAD) has greatly increased and it has become a major cause of death in adults. In the drug-eluting stent (DES) era, coronary artery stenting reduces the incidence of acute vascular events after percutaneous coronary intervention (PCI) to <1%. 1 However, in-stent restenosis (ISR) and stent thrombosis (ST) remain significant clinical problems to be solved. 2 The apparent rate of ISR is 30-40% in PTCA, 15-30% with bare metal stents (BMS), and <10% in DES, and the incidence of ST is 0.5-2.5% with BMS and 0.58-3.3% with DES. 3-5
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Editorial p 424
Many DES are designed and manufactured to overcome restenosis and ST. The abciximab-coated stent was developed for this purposes. Abciximab, a potent antiplatelet agent that blocks the final pathways to platelet aggregation, improves the outcomes of high-risk PCI and decreases the incidence of major adverse cardiac events (MACE). 6-9 Different to other kinds of platelet glycoprotein IIb/IIIa receptor blockers, abciximab also binds to CD11b/18 (Mac-1) on vascular endothelial cells (ECs) and macrophages, thereby inhibiting the inflammatory response and smooth muscle cell (SMC) proliferation after vascular injury. 10- 15 We recently demonstrated that the abciximab-coated stent has an inhibitory effect on coronary restenosis and revascularization, 16-18 so the purpose of the present study was to investigate the safety and clinical efficacy of implantation of the abciximab-coated stent compared with BMS.
Methods

Study Design and Population
We performed a prospective, randomized trial to compare the effects of the abciximab-coated stent, which was implanted in 95 patients, with those of conventional BMS implanted in 93 patients for de novo coronary lesions. The inclusion criteria were CAD patients who were scheduled to undergo elective PCI for single de novo lesions in native coronary
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arteries having a diameter between 2.5 and 4.0 mm and critical stenosis (>70%) on angiography. Patients with graftvessel stenosis, cardiogenic shock, left ventricular ejection fraction <35% or contraindications for antiplatelet agents were excluded from the study.
All procedures were performed by standard techniques: randomly selected stents were deployed at 10-20 atm after predilation with a balloon catheter. In cases of residual stenosis after stenting, adjunct balloon angioplasty was performed. None of the patients received glycoprotein IIb/ IIIa receptor blockers. All patients received aspirin (300 mg ≥12 h before stent implantation and 100-200 mg/day indefinitely) and ticlopidine (500 mg ≥6 h before stent implantation and 250 mg/day for 2 months) or clopidogrel (300 mg ≥6 h before stent implantation and 75 mg/day for 2 months). Heparin was administered as a 5,000-unit bolus followed by 1,000 units/h and an additional 5,000 units immediately before PCI to keep the activated clotting time at 250-300 s. Clinical evaluation was done for 2 years to assess patient symptom frequency and cardiac event rates. The clinical primary endpoint was the composite of cardiac death, any myocardial infarction (MI), and need for percutaneous or surgical revascularization of the target lesion or vessel during the evaluation period, and the secondary endpoint was neointimal hyperplasia, which was measured by intravascular ultrasound (IVUS) at 6-month follow-up coronary angiography (CAG) after the procedure.
The study protocol was reviewed and approved in sequence by the Ministry of Health and Welfare and the Ethics Committee of Chonnam National University Hospital, and informed consent was given by all patients.
Manufacture of Abciximab-Coated Stent
Abciximab-coated stents were used according to the protocol previously described. 17, 18 Briefly, a plasma polymerization reaction was performed to attach amine radicals to the stent surface. Stents were fixed in a tubular reactor, which was made of a Pyrex glass tube, and the pressure was decreased to <5 mTorr. For the attachment of amine radicals to the stent surface, diaminocyclohexane monomer was drifted into the tubular reactor at a constant dose, and plasma was generated using a radiofrequency power generator. The abciximab used was a human-murine chimeric antibody Fab fragment (c7E3 Fab) that blocks the glycoprotein IIb/IIIa receptor directly. The carboxy radical of abciximab was introduced to the amine radicals attached to the stent to achieve covalent bonding and improved attachment between the stent and abciximab. The abciximab coating on the surface of the stent was confirmed by scanning electron microscopy. To evaluate the release kinetics of abciximab from the stent, the stent was placed in a glass vial and immersed in 100 ml of phosphate-buffered saline. The amount of abciximab released to the buffer solution was measured using an absorbance test for ultraviolet at 278 nm.
CAG and IVUS
Quantitative diameter measurements of the coronary arteries were obtained by a blinded reviewer using a workstation with dedicated software (Phillips H5000 or Allura DCI program). From 2 orthogonal views, minimal lumen diameter (MLD) and interpolated reference diameter were calculated as a mean. IVUS studies were performed at baseline and repeated at 6 months after the procedure with follow-up angiography. The images were acquired with motorized pullback at a constant speed of 1 mm/s (Galaxy, Boston Scientific, Natick, MA, USA or Endosonics, EndoSonics Corporation, Rancho Cordova, CA, USA). Trained catheterization laboratory personnel performed the IVUS measurements, according to previously described methods. 19 Pre-interventional lesion and proximal and distal reference segment external elastic membrane (EEM), lumen, and plaque and media (P&M = EEM − lumen) cross-sectional areas (CSA) were measured. The lesion was the site with the smallest lumen CSA; if there were multiple image slices with the same minimum lumen CSA, then the slice with the largest EEM and P&M was measured. The proximal and distal reference segments were the least-diseased image slices (largest lumen with least plaque) proximal and distal to the lesion, but within the same segment and before any major side branch. Post-interventional and follow-up stent, lumen, and NIH (stent minus lumen CSA) areas were measured. KIM SS et al.
Definitions
Successful PCI was defined as a patent vessel at the treatment site with anterograde TIMI 3 flow and angiographic residual stenosis <20% without occurrence of any MACE (MI, acute or subacute stent occlusion, need for coronary bypass or target lesion revascularization). ISR was defined as an instent luminal diameter stenosis ≥50%. Late lumen loss was defined as the difference between the MLD immediately after stenting and the MLD at follow-up. Acute MI was defined as the elevated cardiac biomarkers with ischemic symptoms or ischemic changes on the ECG or imaging evidence of new loss of viable myocardium or new regional wall motion abnormality. ST was defined as an acute coronary syndrome with angiographic documentation of either vessel occlusion (TIMI 0 or 1) or thrombus within or adjacent to a previously successfully stented vessel (TIMI 1 or 2). Kaplan-Meier plots of cumulative major adverse cardiac event (MACE)-free survival rate and cumulative in-stent restenosis (ISR) incidence rate for abciximab-coated stent and control bare metal stent. There was a trend of lower incidences of total MACE and ISR in the abciximab-coated stent group compared with the control stent group for 2-year clinical follow-up.
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during follow-up were analyzed using the Kaplan-Meier method. A value of P<0.05 was considered significant.
Results
Baseline and Procedural Characteristics
The baseline clinical characteristics are summarized in Table 1 . There were no significant differences between the 2 groups in age, gender, risk factors for CAD, clinical presentation or left ventricular ejection fraction. Procedural characteristics are summarized in Table 2 . PCI was performed with a success rate of 100% in both groups without any complications associated with the procedure. There were no significant differences between the 2 groups in target vessels or the number of diseased vessels, except for lesion length and lesion type.
Clinical Follow-up
The 2-year clinical follow-up was completed in 82 patients (86%) in the abciximab-coated stent group and in 82 patients (88%) in the control stent group. During follow up, there were no cardiac deaths or MI in the abciximab-coated stent group. There were 17 cases of ISR (21.0%) in the abciximabcoated stent group compared with 22 (26.8%) in the control BMS group. There were no statistically significant differences in the incidences of MACE and ISR in the abciximabcoated stent group compared with the control stent group (Table 3, Figure) . ST did not occur at 2-year follow-up, despite of the use of short-duration dual antiplatelet therapy.
IVUS Analysis
Serial IVUS measurements are shown in Table 4 . Baseline stent and reference measurements were similar between the 2 groups. At follow-up IVUS, the intra-stent lumen area was larger in the abciximab-coated stent group compared with the control stent group (5.7±1.6 mm 2 vs 4.2±0.8 mm 2 , P= 0.001), and the intra-stent neointimal hyperplasia (NIH) area was smaller (+2.0±1.6 mm 2 vs +3.4±1.7 mm 2 , respectively; P=0.001).
Discussion
This study is the first randomized, prospective clinical trial evaluating the medium-term outcome of abciximab-coated stent implantation in patients with CAD. The abciximabcoated stent was safe to use and inhibited neointimal hyperplasia but failed to prove superior clinical efficacy compared with BMS at 2-year clinical follow up.
The DES is a device releasing into the bloodstream single or multiple bioactive agents that affect tissues adjacent to the stent. Avoiding systemic toxicity, stent-based local drug release at the site of vascular injury via a polymer-coated stent is an attractive method of achieving an effective local concentration of a drug. 20 Abciximab is a platelet glycoprotein IIb/IIIa inhibitor, which are the most potent antiplatelet agents currently available, exerting their effect by blocking the final common pathway of platelet aggregation. The use of abciximab in patients with acute coronary syndrome is associated with reductions in the magnitude of the rise in the levels of circulating inflammatory markers such as C-reactive protein, interleukin-6, and tumor necrosis factor-α, which increase over the 24-48 h after PCI. Abciximab administration also decreases the levels of these inflammatory markers after stent implantation. 21 The effect may be caused by the interaction between CD11b/CD18 (macrophage-1 receptor), which is a receptor located on the surface of neutrophils and monocytes, and abciximab. The interac- 
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tion between CD11b/18 and abciximab results in the inhibition of cell-to-cell adhesion and interaction between cells and the extracellular matrix. 13-15, 22 Also, abciximab has an affinity for the vitronectin receptor on SMCs, ECs, and platelets and the blockade of this receptor by abciximab inhibits the migration and proliferation of SMC after stenting and may prevent ISR. 10-12 Follow-p IVUS at 6 months showed a larger intra-stent lumen area and smaller neointimal area in the abciximab stent group, which suggested an anti-restenotic effect of the coated stent. According to our previous reports, patients who received the abciximab stent were free of procedure-related complications, and the incidence of in-hospital, 30 day MACE was low, especially ST, which did not occur in any of the abciximab-coated stent group. 18 Unfortunately, the beneficial effects of the abciximab-coated stent were not maintained out to 2 years in a real-world population.
These results are less favorable than those of sirolimuseluting stents (SES). In several trials, ISR with SES was 8.2-9.4% during long-term clinical follow-up. 20, 23 However, there have been safety concerns with DES, because of ST. 24 ST is an uncommon but serious complication of coronary artery stenting that often presents as death or MI. In several trials, the incidence of ST was 0.58-1.3% with DES. 3, 4 In the present study ST did not occur in the abciximab stent group at 2 year follow-up. Although the patient number was relatively small, the absence of episodes of acute MI by acute or subacute thrombotic occlusion during the 2 year follow-up in patients who received an abciximab-coated stent may suggest that platelet aggregation was effectively inhibited by abciximab and that this effect could be maintained. Also, the optimal duration of dual antiplatelet therapy has not been determined for DES. In the abciximab-coated stent group, postprocedural clopidogrel or ticlopidine was given for 2 months, according to the protocol, whereas it was prescribed for a more prolonged period of time in the trials using other DES. In spite of the use of short duration dual antiplatelet therapy, ST did not occur after clopidogrel or ticlopidine was stopped in the abciximab-coated stent group.
Study Limitations
One of the main limitations is that this clinical study included only 188 patients undergoing de novo, single vessel stenting in a single center and therefore the present trial is underpowered to reveal potential small differences in the primary endpoints. These findings should be confirmed by the results of the large-scale, prospective randomized trials.
Conclusion
Two-year clinical follow up showed no statistical superiority of the abciximab-coated stent over BMS. The abciximabcoated stent was safe and inhibited neointimal hyperplasia, but did not improve clinical outcomes at 2 years after stent implantation.
